# OnCo record resistance (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/resistance/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "resistance" ;
  schema:name "Drug resistance (primary and acquired)"@en ;
  schema:alternateName "acquired resistance"@en, "primary resistance"@en, "adaptive resistance"@en, "pre-existing resistance"@en, "resistance mechanism"@en, "resistance mechanisms"@en, "resistant clone"@en, "resistant clones"@en, "resistant subclone"@en, "resistant subclones"@en, "bypass pathways"@en, "bypass signalling"@en, "bypass resistance"@en, "chemoresistance"@en, "chemoresistant"@en, "chemotherapy resistance"@en, "TKI resistance"@en, "TKI-resistant"@en, "drug-resistant"@en, "therapy-resistant"@en, "become resistant"@en, "becomes resistant"@en, "escape mechanism"@en, "escape mechanisms"@en, "escape mutation"@en, "escape mutations"@en, "reversion mutations"@en, "BRCA reversion"@en, "on-target mutations"@en, "compound resistance mutations"@en, "confers resistance"@en, "emergence of resistance"@en, "overcome resistance"@en, "resistance alteration"@en, "resistance pathway"@en, "resistant disease"@en ;
  schema:description "Why cancer drugs stop working: the tumour either never depended on the target or evolves around the block."@en ;
  schema:url <https://onco.cc/terms/resistance/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Drug_resistance> ;
  owl:sameAs <http://www.wikidata.org/entity/Q12147416> ;
  schema:citation <https://en.wikipedia.org/wiki/Drug_resistance> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/>, <https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/>, <https://onco.cc/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/>, <https://onco.cc/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/> .